Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$41.54 USD
-0.80 (-1.89%)
Updated May 23, 2024 04:00 PM ET
After-Market: $41.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BMY 41.54 -0.80(-1.89%)
Will BMY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMY
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
BMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Walmart Earnings & the State of the Consumer
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Other News for BMY
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
(BMY) - Analyzing Bristol-Myers Squibb's Short Interest
Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity
Bristol-Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity